All In Biotech

Drug Trial Radar · NCT07024732

A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jun 23, 2025

Primary completion

Apr 7, 2026

Study completion Apr 7, 2026

Sponsor

Lead sponsor
EyevensysIndustry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration

Conditions

  • Dry Age Related Macular Degeneration

Interventions

  • PST-611Biological

    PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Screening to week 16

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Cochin

    Paris, France

  • CHU de Grenoble-Hôpital Michallon

    Grenoble, France, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.